hepatocellular carcinoma
Conditions
Interventions
experimental group:propanolol
control group:Don't take any drug which has definite curative effect to prevent the recurrence of hepatocellular carcinoma
Sponsors
Institute of Hepatobiliary Surgery, Southwest Hospital,Third Military Medical University, PLA
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: (1) Aged from 18 years to 70 years male and female, the postoperative patient is diagnosed as hepatocellular carcinoma by pathological; (2) There was no absolute contraindication before operation, no distant metastasis or large vessel invasion, his (her) tumor should be totally removed by curative resection (RFA or operation); (3) The preoperative Child-Pugh Score should be A (5,6) or B7 (without ascites), and the BCLC stage was A or B stage; (4) Inactive hepatitis; (5) The functional status score of ECOG was 0. There were no obvious cardiac or pulmonary dysfunction or other organ diseases affecting liver function; (6) Avoid the obvious damage to liver function during operation; (7) The subjects understand his condition and know the risks associated with the use of beta blockers in the prevention of HCC recurrence; (8) Voluntary test,informed consent was signed before voluntary medication.
Exclusion criteria
Exclusion criteria: (1) Patients allergic to propranolol hydrochloride; (2) Prior to surgery, patients were received any other treatment for liver cancer, such as liver cancer resection, liver transplantation, interventional therapy, ablation, radiotherapy, chemotherapy or other systemic anti liver cancer treatment; (3) Patients with other systemic tumors; (4) Patients with positive pathological margins or tumor recurrence within 8 weeks after operation; (5) Patients with sinus bradycardia (heart rate less than 60 BPM) and in patients with sick sinus syndrome; (6) Patients with bronchial asthma, chronic obstructive bronchial disease, and history of bronchospasm; (7) Patients with central nervous system diseases, mental illness, or other uncontrollable severe diseases; (8) Patients with II-III degree atrioventricular block; (9) Patients with diabetes mellitus; (10) Patients with renal failure; (11) Patients who use beta blockers to treat with portal hypertension or arrhythmia hypertension at present; (12) Patients with low blood pressure (systolic pressure<90 mmHg, diastolic pressure<60 mmHg); (13) Patients with severe heart failure and acute pulmonary edema; (14) Patients with atrial fibrillation or atrial flutter; (15) Pregnant or lactating women; (16) Patients who are participating in any other clinical trial currently.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| recurernce rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| disease-free survival, DFS;overall survival, OS; | — |
Countries
China
Contacts
Public ContactFeng Xia
Institute of Hepatobiliary Surgery, Southwest Hospital,Third Military Medical University, PLA
Outcome results
None listed